A laboratory developed test, offered exclusively by InterVenn Oncology, can be used by physicians or HCPs to assess whether a patient is likely to benefit from immune checkpoint inhibitor therapy, specifically nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) or pembrolizumab (Keytruda®) monotherapy.
Request A Kit
Now, before starting therapy, you can identify metastatic melanoma patients who are "Likely" or "Unlikely to Benefit" from certain immunotherapies.
- Allows for shared decision making with your patients
- Aids in discussion for treatment alternatives
- May help with trial enrollment
Simple and Powerful Results
In patients with advanced melanoma and a "Likely to Benefit" result from the DAWN IO Melanoma test, our data suggests an increased median progression-free survival of approximately five times compared to the "Unlikely to Benefit" patients when receiving immune checkpoint inhibitors (specifically nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) or pembrolizumab (Keytruda®) monotherapy).
INTERVENN’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The DAWN IO Melanoma test was developed, and its performance characteristics were determined by INTERVENN. The DAWN IO Melanoma test has not been cleared or approved by the U.S. Food and Drug Administration. INTERVENN's clinical laboratory is regulated under CLIA to perform high-complexity testing. The DAWN IO Melanoma test is intended for clinical purposes.